2059 related articles for article (PubMed ID: 9652737)
1. Expression of dominant negative Jun inhibits elevated AP-1 and NF-kappaB transactivation and suppresses anchorage independent growth of HPV immortalized human keratinocytes.
Li JJ; Rhim JS; Schlegel R; Vousden KH; Colburn NH
Oncogene; 1998 May; 16(21):2711-21. PubMed ID: 9652737
[TBL] [Abstract][Full Text] [Related]
2. AP-1 transrepressing retinoic acid does not deplete coactivators or AP-1 monomers but may target specific Jun or Fos containing dimers.
Suzukawa K; Colburn NH
Oncogene; 2002 Mar; 21(14):2181-90. PubMed ID: 11948401
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of both nuclear factor-kappaB and activator protein-1 activation block the neoplastic transformation response.
Li JJ; Westergaard C; Ghosh P; Colburn NH
Cancer Res; 1997 Aug; 57(16):3569-76. PubMed ID: 9270030
[TBL] [Abstract][Full Text] [Related]
4. Conversion of HPV 18 positive non-tumorigenic HeLa-fibroblast hybrids to invasive growth involves loss of TNF-alpha mediated repression of viral transcription and modification of the AP-1 transcription complex.
Soto U; Das BC; Lengert M; Finzer P; zur Hausen H; Rösl F
Oncogene; 1999 May; 18(21):3187-98. PubMed ID: 10359524
[TBL] [Abstract][Full Text] [Related]
5. Differential inhibition of UVB-induced AP-1 and NF-kappaB transactivation by components of the jun bZIP domain.
Cooper S; Ranger-Moore J; Bowden TG
Mol Carcinog; 2005 Jun; 43(2):108-16. PubMed ID: 15791649
[TBL] [Abstract][Full Text] [Related]
6. High levels of phosphorylated c-Jun, Fra-1, Fra-2 and ATF-2 proteins correlate with malignant phenotypes in the multistage mouse skin carcinogenesis model.
Zoumpourlis V; Papassava P; Linardopoulos S; Gillespie D; Balmain A; Pintzas A
Oncogene; 2000 Aug; 19(35):4011-21. PubMed ID: 10962557
[TBL] [Abstract][Full Text] [Related]
7. Activator protein 1 transcription factors are fundamental to v-rasHa-induced changes in gene expression in neoplastic keratinocytes.
Rutberg SE; Adams TL; Glick A; Bonovich MT; Vinson C; Yuspa SH
Cancer Res; 2000 Nov; 60(22):6332-8. PubMed ID: 11103794
[TBL] [Abstract][Full Text] [Related]
8. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
Zerbini LF; Wang Y; Cho JY; Libermann TA
Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
[TBL] [Abstract][Full Text] [Related]
9. B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos.
Echlin DR; Tae HJ; Mitin N; Taparowsky EJ
Oncogene; 2000 Mar; 19(14):1752-63. PubMed ID: 10777209
[TBL] [Abstract][Full Text] [Related]
10. Opposing activities of c-Fos and Fra-2 on AP-1 regulated transcriptional activity in mouse keratinocytes induced to differentiate by calcium and phorbol esters.
Rutberg SE; Saez E; Lo S; Jang SI; Markova N; Spiegelman BM; Yuspa SH
Oncogene; 1997 Sep; 15(11):1337-46. PubMed ID: 9315102
[TBL] [Abstract][Full Text] [Related]
11. Expression of human p53 requires synergistic activation of transcription from the p53 promoter by AP-1, NF-kappaB and Myc/Max.
Kirch HC; Flaswinkel S; Rumpf H; Brockmann D; Esche H
Oncogene; 1999 Apr; 18(17):2728-38. PubMed ID: 10348347
[TBL] [Abstract][Full Text] [Related]
12. Activation and inhibition of the AP-1 complex in human breast cancer cells.
Chen TK; Smith LM; Gebhardt DK; Birrer MJ; Brown PH
Mol Carcinog; 1996 Mar; 15(3):215-26. PubMed ID: 8597534
[TBL] [Abstract][Full Text] [Related]
13. Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation.
Yang HS; Knies JL; Stark C; Colburn NH
Oncogene; 2003 Jun; 22(24):3712-20. PubMed ID: 12802278
[TBL] [Abstract][Full Text] [Related]
14. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes.
Nees M; Geoghegan JM; Hyman T; Frank S; Miller L; Woodworth CD
J Virol; 2001 May; 75(9):4283-96. PubMed ID: 11287578
[TBL] [Abstract][Full Text] [Related]
15. Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation.
Watts RG; Huang C; Young MR; Li JJ; Dong Z; Pennie WD; Colburn NH
Oncogene; 1998 Dec; 17(26):3493-8. PubMed ID: 10030673
[TBL] [Abstract][Full Text] [Related]
16. Involvement of Rel, Fos, and Jun proteins in binding activity to the IL-2 promoter CD28 response element/AP-1 sequence in human T cells.
McGuire KL; Iacobelli M
J Immunol; 1997 Aug; 159(3):1319-27. PubMed ID: 9233628
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional activation of the human papillomavirus-16 P97 promoter by an 88-nucleotide enhancer containing distinct cell-dependent and AP-1-responsive modules.
Cripe TP; Alderborn A; Anderson RD; Parkkinen S; Bergman P; Haugen TH; Pettersson U; Turek LP
New Biol; 1990 May; 2(5):450-63. PubMed ID: 1963084
[TBL] [Abstract][Full Text] [Related]
18. Structure and transcriptional regulation of BKJ, a novel AP-1 target gene activated during jun- or fos-induced fibroblast transformation.
Hartl M; Bister K
Oncogene; 1998 Dec; 17(22):2901-13. PubMed ID: 9879996
[TBL] [Abstract][Full Text] [Related]
19. Opposing functions of ATF2 and Fos-like transcription factors in c-Jun-mediated myogenin expression and terminal differentiation of avian myoblasts.
Daury L; Busson M; Tourkine N; Casas F; Cassar-Malek I; Wrutniak-Cabello C; Castellazzi M; Cabello G
Oncogene; 2001 Nov; 20(55):7998-8008. PubMed ID: 11753683
[TBL] [Abstract][Full Text] [Related]
20. Regulation of epidermal growth factor receptor by activated H-ras and V-myc oncogenes in mouse Balb/3T3 cells: possible roles of AP-1.
Okimoto T; Kohno K; Kuwano M; Gopas J; Kung HF; Ono M
Oncogene; 1996 Apr; 12(8):1625-33. PubMed ID: 8622882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
